Cargando…

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

INTRODUCTION: The objective of this study was to assess the effect of sitagliptin on insulin dose in patients with inadequately controlled type 2 diabetes who titrate basal insulin to a target fasting glucose level after initiating sitagliptin. METHODS: This was a multicenter, randomized, double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathieu, Chantal, Shankar, R. Ravi, Lorber, Daniel, Umpierrez, Guillermo, Wu, Fan, Xu, Lei, Golm, Gregory T., Latham, Melanie, Kaufman, Keith D., Engel, Samuel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478181/ https://www.ncbi.nlm.nih.gov/pubmed/25820927 http://dx.doi.org/10.1007/s13300-015-0105-3

Ejemplares similares

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
por: Roussel, Ronan, et al.
Publicado: (2018)

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol
por: Levy, Natalie, et al.
Publicado: (2015)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Addendum to: The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol
por: Levy, Natalie, et al.
Publicado: (2015)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control
por: Umpierrez, Guillermo E., et al.
Publicado: (2019)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
por: Owens, D R, et al.
Publicado: (2011)

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
por: Shankar, R Ravi, et al.
Publicado: (2016)

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
por: Williams-Herman, Debora, et al.
Publicado: (2010)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial
por: Bae, Jae Hyun, et al.
Publicado: (2022)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
por: Arjona Ferreira, Juan Camilo, et al.
Publicado: (2013)

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
por: Sarmiento-Ortega, Victor Enrique, et al.
Publicado: (2023)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
por: Rosenstock, Julio, et al.
Publicado: (2017)

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Yan, Jinhua, et al.
Publicado: (2019)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
por: Miller, Sam, et al.
Publicado: (2018)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Basal insulin titration by the app
por: Vangoitsenhoven, Roman, et al.
Publicado: (2023)

Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations
por: Deerochanawong, Chaicharn, et al.
Publicado: (2017)

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
por: Ling, James, et al.
Publicado: (2021)

‘Titrating’ simulation training intensity
por: Mileder, Lukas
Publicado: (2018)

Take Control: A randomized trial evaluating the efficacy and safety of self‐ versus physician‐managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes
por: Russell‐Jones, David, et al.
Publicado: (2019)

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial
por: Wysham, Carol, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_18ofoddialoeiqlqtpa97vs2r2